Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.
• Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of 0.5% on a constant currency basis.
• Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an increase of 3.0%, as reported.
• GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Non- GAAP diluted EPS was $1.23, an increase of 4.4%.
• GAAP gross profit as a percentage of net sales was 66.7%, an increase of 2.5%. Non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%, an increase of 1.4%. “Third quarter revenue finished at $764 million, down slightly from the prior year quarter,” commented Keith Pfeil, President and Chief Executive Officer. “U.S. Spine faced difficult prior year comparables, growing 2% in the third quarter, as compared to double digit growth in the prior year quarter. On an average two-year basis, the U.S. Spine business is growing mid-single digits, reflecting our ability to capture share in the market, as we lead with innovation and differentiation. Our Enabling Technologies strategy continued to make progress, delivering revenue growth of 24%, while simultaneously deploying 73% more robot and navigation units as compared to the prior year quarter, reflecting continued strong demand for our technology and execution against our capital deployment plan. We remain focused on our long-term strategy of achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence ecosystem.”
“Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation,” said Kyle Kline, Chief Financial Officer. “Our performance reflects disciplined execution across the business, which positions us to deliver sustained earnings growth, cash generation, and enhanced shareholder returns. To further this commitment, our Board has authorized a $500 million increase to our existing share repurchase program, which reflects confidence in our long-term growth profile and underlying earnings and cash generation prowess.”
Worldwide net sales for the third quarter of 2026 were $763.7 million, an as- reported decrease of 0.7% over the third quarter of 2025. U.S. net sales for the third quarter of 2026 increased by 0.5% compared to the third quarter of 2025. International net sales decreased by 5.7% over the third quarter of 2025 on an as-reported basis and decreased by 5.0% on a constant currency basis.
GAAP net income for the third quarter of 2026 was $141.2 million, an increase of 18.7% over the same period in the prior year. The increase in GAAP net income was primarily driven by the decrease in cost of sales and operating expenses, decreasing $19.6 million and $25.9 million, respectively, in comparison to the third quarter of 2025. GAAP diluted EPS for the third quarter was $1.04, compared to $0.88 for the third quarter of 2025, an increase of 18.2%. Non-GAAP diluted EPS for the third quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.23, compared to $1.18 in the third quarter of 2025, an increase of 4.4%.
The Company is updating its guidance for full-year 2026 revenue to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, representing 5.1% revenue growth as compared to fiscal 2025. The Company reaffirms its full-year fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS.
Globus Medical will hold a teleconference to discuss its 2026 third quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news- events/events-webcasts.
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.
Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), management uses certain non- GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, merger and acquisition related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represent the change in fair value of business- acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.
In addition, for the period ended September 30, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non- recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP adjusted gross profit, which excludes the impacts of any inventory acquisition- related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends.
Additionally, for the period ended September 30, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business sales and revenue growth, excluding the contribution from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide insight to how the Company is performing without the impact of the Nevro acquisition.
Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP adjusted gross profit, free cash flow, constant currency net sales growth, base business revenue growth, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three and nine months ended September 30, 2026 and 2025.
We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition- related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments, and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income.
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward- looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company,” “Globus,” “Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.
On November 2, 2026, our Board of Directors authorized the Company to repurchase an additional $500 million of shares of its common stock under our existing share repurchase program (the “Repurchase Program”), which does not have an expiration date. Repurchases under the Repurchase Program may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and actual number of shares repurchased under the Repurchase Program will be determined by management at its discretion and will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements and alternative investment opportunities. The Repurchase Program has no time limit and may be suspended for periods or discontinued at any time.
(In thousands, except share and per share values) ASSETS September 30, December 31, Current assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 441,272 $ 526,156 equivalents Short-term marketable 76,163 31,087 securities Accounts receivable, net of allowances 675,297 678,938 $47,866 and $33,434, respectively Inventories 824,144 759,277 Prepaid expenses and other current 116,437 65,426 assets Income taxes 48,651 64,727 receivable Total current assets 2,181,964 2,125,611 Property and 532,760 564,452 equipment, net Operating lease right 56,768 63,786 of use assets Long-term marketable 353,738 71,819 securities Intangible assets, 667,468 745,064 net Goodwill 1,453,561 1,435,033 Other assets 75,993 78,781 Deferred income taxes 205,941 218,215 Total assets $ 5,528,193 $ 5,302,761 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 107,428 $ 98,852 Accrued expenses 326,858 333,586 Operating lease 14,176 14,738 liabilities Income taxes payable 5,844 4,155 Business acquisition 25,820 19,513 liabilities Deferred revenue 27,812 27,655 Total current 507,938 498,499 liabilities Business acquisition liabilities, net of 80,547 81,995 current portion Operating lease 93,378 103,918 liabilities Deferred income taxes and other tax 31,603 23,756 liabilities Other liabilities 18,477 21,343 Total liabilities 731,943 729,511 Equity: Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 110 113 110,235,170 and 112,625,126 shares at September 30, 2026 and December 31, 2025, respectively Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22 22 22,430,097 and 22,430,097 shares at September 30, 2026 and December 31, 2025, respectively Additional paid-in 3,259,292 3,169,812 capital Accumulated other comprehensive 11,336 15,346 income/(loss) Retained earnings 1,525,490 1,387,957 Total equity 4,796,250 4,573,250 Total liabilities and $ 5,528,193 $ 5,302,761 equity
(In thousands) Nine Months Ended Cash flows from operating September 30, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 417,042 $ 397,274 Adjustments to reconcile net income to net cash provided by operating activities: Bargain purchase gain -1,118 -114,361 Depreciation and 209,730 207,357 amortization Provision for excess and obsolete 14,671 15,988 inventory Amortization of acquisition accounting — 19,631 fair value step up Stock-based compensation 37,743 38,361 expense Allowance for expected 13,954 5,311 credit losses Change in fair value of business 16,231 2,668 acquisition liabilities Change in deferred income 24,778 525 taxes (Gain)/loss on disposal of 6,765 8,438 assets, net Payment of business acquisition-related -2,965 -16,425 liabilities Net (gain)/loss from foreign currency 277 -14,621 adjustment (Increase) decrease in: Accounts receivable -12,345 11,971 Inventories -60,086 -17,420 Prepaid expenses and other 3,826 -6,689 assets Increase (decrease) in: Accounts payable 6,664 -654 Accrued expenses and other -15,375 25,442 liabilities Income taxes 17,540 -57,936 payable/receivable Net cash provided by/(used in) operating 677,332 504,860 activities Cash flows from investing activities: Purchases of marketable -398,841 -37,109 securities Sales and maturities of marketable 66,805 174,238 securities Purchases of property and -113,172 -118,482 equipment Acquisition of businesses, net of cash acquired and purchases of -22,417 -262,212 intangible and other assets Net cash provided by/(used in) investing -467,625 -243,565 activities Cash flows from financing activities: Payment of business acquisition-related -17,417 -11,240 liabilities Net proceeds from exercise of stock 52,812 26,999 options Payments related to tax withholdings for -3,453 -2,698 share-based compensation Repurchase of common stock -279,001 -255,451 Repayment of senior — -449,985 convertible notes Net cash provided by/(used in) financing -247,059 -692,375 activities Effect of foreign exchange -1,117 18,411 rates on cash Net increase/(decrease) in cash, cash -38,469 -412,669 equivalents, and restricted cash Cash, cash equivalents, and restricted 526,156 784,438 cash at beginning of period Cash, cash equivalents, and restricted $ 487,687 $ 371,769 cash at end of period Supplemental disclosures of cash flow information: Income taxes paid, net $ 65,804 $ 95,096 Non-cash investing and financing activities: Accrued purchases of property and $ 12,209 $ 13,454 equipment
The following table provides a reconciliation of cash and cash equivalents reported on our condensed consolidated balance sheets to the total of the cash, cash equivalents, and restricted cash reported within our condensed consolidated statements of cash flows.
As of September (In thousands) 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents shown in the $ 441,272 $ 371,769 condensed consolidated balance sheets Restricted escrow deposits included in 46,415 — prepaid expenses and other current assets Total cash, cash equivalents, and restricted cash shown in the $ 487,687 $ 371,769 condensed consolidated statements of cash flows
(1) Merger and acquisition-related costs represent certain costs associated with acquisitions. These costs, presented on a before-tax effect basis, are included in Non-GAAP Merger and Acquisition-related Costs Table. Non-GAAP Merger and Acquisition-related Costs Table:
(b) Primarily comprised of severance, share-based compensation and termination fees. Non-GAAP Net Income Reconciliation Table:
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table for the detail of these costs. Non-GAAP Gross Profit Reconciliation Table:
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs.
Full text with the tables
Exhibit 99.1
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million
Increase to the Share Repurchase Program
AUDUBON, PA., November 5, 2026: Globus Medical, Inc. (NYSE: GMED), a leading
musculoskeletal technology company, today announced its financial results for
the third quarter ended September 30, 2026.
Third Quarter 2026 Results
• Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of
0.5% on a constant currency basis.
• Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an
increase of 3.0%, as reported.
• GAAP net income for the quarter was $141.2 million.
• GAAP diluted earnings per share (“EPS”) was $1.04, an increase of 18.2%. Non-
GAAP diluted EPS was $1.23, an increase of 4.4%.
• GAAP gross profit as a percentage of net sales was 66.7%, an increase of 2.5%.
Non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%, an increase
of 1.4%.
“Third quarter revenue finished at $764 million, down slightly from the prior
year quarter,” commented Keith Pfeil, President and Chief Executive Officer.
“U.S. Spine faced difficult prior year comparables, growing 2% in the third
quarter, as compared to double digit growth in the prior year quarter. On an
average two-year basis, the U.S. Spine business is growing mid-single digits,
reflecting our ability to capture share in the market, as we lead with
innovation and differentiation. Our Enabling Technologies strategy continued to
make progress, delivering revenue growth of 24%, while simultaneously deploying
73% more robot and navigation units as compared to the prior year quarter,
reflecting continued strong demand for our technology and execution against our
capital deployment plan. We remain focused on our long-term strategy of
achieving improved surgical outcomes through the Globus ecosystem, bringing
together patient selection, surgical techniques with complementary implants and
technology to drive the surgical procedure, through a closed-loop surgical
intelligence ecosystem.”
“Our third quarter results highlight our Company’s commitment to delivering
consistent adjusted gross profit margin expansion, bottom-line profit, and free
cash flow generation, as we delivered the eighth straight quarter of sequential
adjusted gross profit margin expansion and record quarterly operating cash flow
and free cash flow generation,” said Kyle Kline, Chief Financial Officer. “Our
performance reflects disciplined execution across the business, which positions
us to deliver sustained earnings growth, cash generation, and enhanced
shareholder returns. To further this commitment, our Board has authorized a $500
million increase to our existing share repurchase program, which reflects
confidence in our long-term growth profile and underlying earnings and cash
generation prowess.”
Worldwide net sales for the third quarter of 2026 were $763.7 million, an as-
reported decrease of 0.7% over the third quarter of 2025. U.S. net sales for the
third quarter of 2026 increased by 0.5% compared to the third quarter of 2025.
International net sales decreased by 5.7% over the third quarter of 2025 on an
as-reported basis and decreased by 5.0% on a constant currency basis.
GAAP net income for the third quarter of 2026 was $141.2 million, an increase of
18.7% over the same period in the prior year. The increase in GAAP net income
was primarily driven by the decrease in cost of sales and operating expenses,
decreasing $19.6 million and $25.9 million, respectively, in comparison to the
third quarter of 2025. GAAP diluted EPS for the third quarter was $1.04,
compared to $0.88 for the third quarter of 2025, an increase of 18.2%. Non-GAAP
diluted EPS for the third quarter of 2026, which excludes, among other costs,
amortization of intangibles, merger and acquisition-related costs, and
restructuring-related costs, was $1.23, compared to $1.18 in the third quarter
of 2025, an increase of 4.4%.
2026 Annual Guidance
The Company is updating its guidance for full-year 2026 revenue to $3.09 billion
from the previous range of $3.18 billion to $3.22 billion, representing 5.1%
revenue growth as compared to fiscal 2025. The Company reaffirms its full-year
fiscal 2026 non-GAAP fully diluted EPS guidance to be in the range of $4.95 to
$5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully
diluted EPS.
Conference Call Information
Globus Medical will hold a teleconference to discuss its 2026 third quarter
results with the investment community at 4:30 p.m. Eastern Time today.
Participants may access the conference call live via webcast on the Investors
page of Globus Medical’s website at http://www.investors.globusmedical.com/news-
events/events-webcasts.
To participate via telephone, please register in advance at this link. Upon
registration, all telephone participants will receive a confirmation email
detailing how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access the call.
The audio archive will be available after the call on the Investor page of the
Globus Medical website.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal technology company
dedicated to solving unmet clinical needs and changing lives. We innovate with
inspired urgency, provide world-class education and clinical support, and
advance care throughout spine, orthopedic trauma, joint reconstruction,
biomaterials and enabling technologies. Additional information can be accessed
at www.globusmedical.com.
Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S.
generally accepted accounting principles (“GAAP”), management uses certain non-
GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents
net income before interest income, net and other non-operating expenses,
provision for income taxes, depreciation and amortization, stock-based
compensation expense, provision for litigation, merger and acquisition related
costs, restructuring related costs, certain foreign currency acquisition-related
impacts, bargain purchase gains, and gains and losses from strategic
investments, is useful as an additional measure of operating performance, and
particularly as a measure of comparative operating performance from period to
period, as it is reflective of changes in pricing decisions, cost controls and
other factors that affect operating performance, and it removes the effect of
our capital structure, asset base, income taxes and interest income and expense.
We no longer include acquisition of in-process research and development as an
adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP
Adjusted EBITDA for planning purposes, including the preparation of our annual
operating budget and financial projections. Provision for litigation represents
costs incurred for litigation settlements or unfavorable verdicts when the loss
is known or considered probable and the amount can be reasonably estimated, or
in the case of a favorable settlement, when income is realized. Merger and
acquisition related costs represent the change in fair value of business-
acquisition-related contingent consideration; costs related to integrating
recently acquired businesses, including but not limited to costs to exit or
convert contractual obligations, severance, retention bonus, duplicative costs
and information system conversion; and specific costs related to the
consummation of the acquisition process such as banker fees, legal fees, and
other acquisition related professional fees. Restructuring related costs include
severance, retention bonus, accelerated stock-based compensation expense, legal
and tax fees for legal entity reorganization and costs associated with
consolidating facilities. We also adjusted for certain foreign currency impacts
related to the acquisition costs and gains/losses on strategic investments
within other assets as we believe these impacts are not a measure of our
operating performance.
In addition, for the period ended September 30, 2026 and for other comparative
periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which
represent net income and diluted EPS excluding the provision for litigation,
amortization of intangibles, merger and acquisition related costs, restructuring
related costs, certain foreign currency impacts, gains and losses from strategic
investments, bargain purchase gains, certain income tax net benefits and non-
recurring tax adjustments, and the tax effects of all of the foregoing
adjustments. We no longer include acquisition of in-process research and
development as an adjustment to non-GAAP net income. We also present non-GAAP
adjusted gross profit, which excludes the impacts of any inventory acquisition-
related costs within cost of goods sold. The tax effect adjustment represents
the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net
income. The tax impact of the non-GAAP adjustments is calculated based on the
consolidated effective tax rate on a GAAP basis, applied to the non-GAAP
adjustments, unless the underlying item has a materially different tax
treatment, in which case the estimated tax rate applicable to the adjustment is
used. We believe these non-GAAP measures are also useful indicators of our
operating performance, and particularly as additional measures of comparative
operating performance from period to period as they remove the effects of the
foregoing items, which we believe are not reflective of underlying business
trends.
Additionally, for the period ended September 30, 2026 and for other comparative
periods, we also define the non-GAAP measure of free cash flow as the net cash
provided by operating activities, adjusted for the impact of restricted cash,
less the cash impact of purchases of property and equipment. We believe that
this financial measure provides meaningful information for evaluating our
overall financial performance for comparative periods as it facilitates an
assessment of funds available to satisfy current and future obligations and fund
acquisitions. Furthermore, the non-GAAP measure of constant currency net sales
growth is calculated by translating current year net sales at the same average
exchange rates in effect during the applicable prior year period. We believe
constant currency net sales growth provides insight to the comparative increase
or decrease in period net sales, in dollar and percentage terms, excluding the
effects of fluctuations in foreign currency exchange rates. We are also
presenting base business sales and revenue growth, excluding the contribution
from Nevro Corp. (“Nevro”), which we acquired in 2025. We believe these provide
insight to how the Company is performing without the impact of the Nevro
acquisition.
Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP
adjusted gross profit, free cash flow, constant currency net sales growth, base
business revenue growth, and day-adjusted basis sales are not calculated in
conformity with GAAP. Non-GAAP financial measures have limitations as analytical
tools and should not be considered in isolation or as a substitute for financial
measures prepared in accordance with GAAP. These measures do not include certain
expenses that may be necessary to evaluate our liquidity or operating results.
Our definitions of these non-GAAP measures may differ from that of other
companies and therefore may not be comparable. The tables included in this
release reconcile the GAAP financial measures to the non-GAAP financial measures
discussed above for the three and nine months ended September 30, 2026 and 2025.
We are unable to present a quantitative reconciliation of our expected fully
diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with
reasonable certainty and without unreasonable effort the impact and timing of
provision for litigation, amortization of intangibles, merger and acquisition-
related costs, restructuring related costs, certain foreign currency
acquisition-related impacts, bargain purchase gains, certain income tax net
benefits from non-recurring tax adjustments, gains and losses from strategic
investments, and the tax effects of all of the foregoing adjustments. The
financial impact of these items is uncertain and is dependent on various
factors, including timing, and could be material to our Consolidated Statements
of Income.
Safe Harbor Statements
All statements included in this press release other than statements of
historical fact are forward-looking statements and may be identified by their
use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other
similar terms. These forward-looking statements are based on our current
assumptions, expectations and estimates of future events and trends. Forward-
looking statements are only predictions and are subject to many risks,
uncertainties and other factors that may affect our businesses and operations
and could cause actual results to differ materially from those predicted. These
risks and uncertainties include, but are not limited to, the risks and costs
associated with health epidemics, pandemics and similar outbreaks, factors
affecting our quarterly results, our ability to manage our growth, our ability
to sustain our profitability, demand for our products, our ability to compete
successfully (including without limitation our ability to convince surgeons to
use our products and our ability to attract and retain sales and other
personnel), our ability to rapidly develop and introduce new products, our
ability to develop and execute on successful business strategies, our ability to
comply with laws and regulations that are or may become applicable to our
businesses, our ability to safeguard our intellectual property, our success in
defending legal proceedings brought against us, trends in the medical device
industry, general economic conditions, the successful integration of businesses
that we have acquired or may acquire in the future, and other risks. For a
discussion of these and other risks, uncertainties, and other factors that could
affect our results, refer to the disclosures contained in our most recent Annual
Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the
“SEC”), including the sections labeled “Risk Factors” and “Cautionary Note
Concerning Forward-Looking Statements,” and in our subsequent filings with the
SEC. These documents are available at www.sec.gov. Moreover, we operate in an
evolving environment. New risk factors and uncertainties emerge from time to
time and it is not possible for us to predict all risk factors and
uncertainties, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking
statements. Given these risks and uncertainties, readers are cautioned not to
place undue reliance on any forward-looking statements. Forward-looking
statements contained in this press release speak only as of the date of this
press release. Except as may be required by applicable law, we undertake no
obligation to update any forward-looking statements as a result of new
information, events or circumstances or other factors arising or coming to our
attention after the date hereof. As used herein, the “Company,” “Globus,”
“Globus Medical,” “we,” “us,” and “our” refers to Globus Medical, Inc.
Share Repurchase Program
On November 2, 2026, our Board of Directors authorized the Company to repurchase
an additional $500 million of shares of its common stock under our existing
share repurchase program (the “Repurchase Program”), which does not have an
expiration date. Repurchases under the Repurchase Program may be made through
privately negotiated transactions or open market transactions, including
pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18
under the Securities Exchange Act of 1934, as amended. The timing and actual
number of shares repurchased under the Repurchase Program will be determined by
management at its discretion and will depend on a variety of factors, including
market price of the shares, general business and market conditions, applicable
legal requirements and alternative investment opportunities. The Repurchase
Program has no time limit and may be suspended for periods or discontinued at
any time.
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(…
t… Th… Ni…
e… Mo… Mo…
p… En… En…
s… Se… Se…
a… 2026 30, 20… 2026 30, 20…
──────────────────────────────────────────────────────────────────────────────
N… $ 76… $ 769… $ 2,… $ 2,1…
s…
C…
of
s…
a…
o…
e…
C…
of
s…
(… 23… 252… 70… 696…
of
a…
of
i…
R…
a… 34… 38,… 10… 111…
d…
S…
g… 28… 313… 87… 860…
a…
a…
A…
of 29… 29,… 88… 88,…
i…
A… 720 -2,… 18… 31,…
c…
R… -43 358 7,… 13,…
c…
O… 17… 137… 51… 310…
i…
O…
i…
n…
I…
i… 8,… 1,4… 20… 3,8…
n…
F…
c… -1… -161 -4… 4,1…
t…
g…
B…
p… — 3,8… 1,… 114…
g…
O… -9… 1,5… 2,… 3,0…
i…
T…
o… 5,… 6,6… 19… 125…
i…
n…
I…
b… 18… 143… 53… 435…
i…
t…
I…
t… 42… 25,… 11… 38,…
p…
N… $ 14… $ 118… $ 41… $ 397…
i…
O…
c…
i…
n…
of
t…
U…
g…
on -2… 30 -3… 347
m…
s…
F…
c… 2,… 658 -2… 17,…
t…
g…
T…
o…
c…
i… 140 688 -4… 17,…
n…
of
t…
C… $ 14… $ 119… $ 41… $ 415…
i…
E…
p…
s…
B… $ 1.… $ 0.88 $ 3.… $ 2.93
D… $ 1.… $ 0.88 $ 3.… $ 2.90
W…
a…
s…
o…
B… 134… 13… 134… 13…
D… 136… 13… 137… 13…
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except
share and per share
values)
ASSETS September 30, December 31,
Current assets: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 441,272 $ 526,156
equivalents
Short-term marketable 76,163 31,087
securities
Accounts receivable,
net of allowances 675,297 678,938
$47,866 and $33,434,
respectively
Inventories 824,144 759,277
Prepaid expenses and
other current 116,437 65,426
assets
Income taxes 48,651 64,727
receivable
Total current assets 2,181,964 2,125,611
Property and 532,760 564,452
equipment, net
Operating lease right 56,768 63,786
of use assets
Long-term marketable 353,738 71,819
securities
Intangible assets, 667,468 745,064
net
Goodwill 1,453,561 1,435,033
Other assets 75,993 78,781
Deferred income taxes 205,941 218,215
Total assets $ 5,528,193 $ 5,302,761
LIABILITIES AND
EQUITY
Current liabilities:
Accounts payable $ 107,428 $ 98,852
Accrued expenses 326,858 333,586
Operating lease 14,176 14,738
liabilities
Income taxes payable 5,844 4,155
Business acquisition 25,820 19,513
liabilities
Deferred revenue 27,812 27,655
Total current 507,938 498,499
liabilities
Business acquisition
liabilities, net of 80,547 81,995
current portion
Operating lease 93,378 103,918
liabilities
Deferred income taxes
and other tax 31,603 23,756
liabilities
Other liabilities 18,477 21,343
Total liabilities 731,943 729,511
Equity:
Class A common stock;
$0.001 par value.
Authorized
500,000,000 shares;
issued
and outstanding 110 113
110,235,170 and
112,625,126 shares at
September 30, 2026
and December 31,
2025, respectively
Class B common stock;
$0.001 par value.
Authorized
275,000,000 shares;
issued
and outstanding 22 22
22,430,097 and
22,430,097 shares at
September 30, 2026
and December 31,
2025, respectively
Additional paid-in 3,259,292 3,169,812
capital
Accumulated other
comprehensive 11,336 15,346
income/(loss)
Retained earnings 1,525,490 1,387,957
Total equity 4,796,250 4,573,250
Total liabilities and $ 5,528,193 $ 5,302,761
equity
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands) Nine Months Ended
Cash flows from operating September 30,
activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 417,042 $ 397,274
Adjustments to reconcile
net income to
net cash provided by
operating
activities:
Bargain purchase gain -1,118 -114,361
Depreciation and 209,730 207,357
amortization
Provision for excess and
obsolete 14,671 15,988
inventory
Amortization of acquisition
accounting — 19,631
fair value step up
Stock-based compensation 37,743 38,361
expense
Allowance for expected 13,954 5,311
credit losses
Change in fair value of
business 16,231 2,668
acquisition liabilities
Change in deferred income 24,778 525
taxes
(Gain)/loss on disposal of 6,765 8,438
assets, net
Payment of business
acquisition-related -2,965 -16,425
liabilities
Net (gain)/loss from
foreign currency 277 -14,621
adjustment
(Increase) decrease in:
Accounts receivable -12,345 11,971
Inventories -60,086 -17,420
Prepaid expenses and other 3,826 -6,689
assets
Increase (decrease) in:
Accounts payable 6,664 -654
Accrued expenses and other -15,375 25,442
liabilities
Income taxes 17,540 -57,936
payable/receivable
Net cash provided by/(used
in) operating 677,332 504,860
activities
Cash flows from investing
activities:
Purchases of marketable -398,841 -37,109
securities
Sales and maturities of
marketable 66,805 174,238
securities
Purchases of property and -113,172 -118,482
equipment
Acquisition of businesses,
net of cash
acquired and purchases of -22,417 -262,212
intangible and
other assets
Net cash provided by/(used
in) investing -467,625 -243,565
activities
Cash flows from financing
activities:
Payment of business
acquisition-related -17,417 -11,240
liabilities
Net proceeds from exercise
of stock 52,812 26,999
options
Payments related to tax
withholdings for -3,453 -2,698
share-based compensation
Repurchase of common stock -279,001 -255,451
Repayment of senior — -449,985
convertible notes
Net cash provided by/(used
in) financing -247,059 -692,375
activities
Effect of foreign exchange -1,117 18,411
rates on cash
Net increase/(decrease) in
cash, cash -38,469 -412,669
equivalents, and restricted
cash
Cash, cash equivalents, and
restricted 526,156 784,438
cash at beginning of period
Cash, cash equivalents, and
restricted $ 487,687 $ 371,769
cash at end of period
Supplemental disclosures of
cash flow
information:
Income taxes paid, net $ 65,804 $ 95,096
Non-cash investing and
financing
activities:
Accrued purchases of
property and $ 12,209 $ 13,454
equipment
The following table provides a reconciliation of cash and cash equivalents
reported on our condensed consolidated balance sheets to the total of the cash,
cash equivalents, and restricted cash reported within our condensed consolidated
statements of cash flows.
As of September
(In thousands) 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash
equivalents shown
in the $ 441,272 $ 371,769
condensed
consolidated
balance sheets
Restricted escrow
deposits included
in 46,415 —
prepaid expenses
and other current
assets
Total cash, cash
equivalents, and
restricted cash
shown in the $ 487,687 $ 371,769
condensed
consolidated
statements of
cash flows
Supplemental Financial Information
Net Sales by Product Category:
Three Nine
Months Months
Ended Ended
(In Septemb… Septem…
thous… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Muscu… $ 728,855 $ 741,009 $ 2,225,… $ 2,027,1…
Solut…
Enabl… 34,864 28,039 87,806 85,387
Techn…
Total
net $ 763,719 $ 769,048 $ 2,313,… $ 2,112,5…
sales
Liquidity and Capital Resources:
(In thousands) 2026 September 30, 2025 December 31,
──────────────────────────────────────────────────────────────────────────────
Cash and cash equivalents $ 441,272 $ 526,156
Short-term marketable 76,163 31,087
securities
Long-term marketable securities 353,738 71,819
Total cash, cash equivalents
and $ 871,173 $ 629,062
marketable securities
The following tables reconcile GAAP to non-GAAP financial measures.
Non-GAAP Adjusted EBITDA Reconciliation Table:
Th… Ni…
(… Mo… Mo…
t… En… En…
e… Se… Se…
p… 2026 30, 20… 2026 30, 20…
──────────────────────────────────────────────────────────────────────────────
N… $ 14… $ 118… $ 41… $ 397…
i…
I…
(… -8… -1,… -2… -3,…
n…
P…
f… 42… 25,… 11… 38,…
i…
t…
D…
a… 70… 71,… 21… 207…
a…
E… 24… 213… 72… 639…
S…
c… 11… 11,… 37… 37,…
e…
P…
f… 3,… 28,… 3,… 24,…
l…
n…
M…
a… 632 4,6… 18… 46,…
a…
c…
N…
(…
l… 911 -946 -2… -2,…
f…
s…
i…
N…
a…
f… -60 -3,… -2… -15…
c…
i…
R… -4… 2,2… 8,… 22,…
c…
B…
p… — -3,… -1… -11…
g…
A… $ 26… $ 252… $ 78… $ 639…
E…
N…
i…
as
a 18.5 15… 18.0 18…
p… % % % %
of
n…
s…
A…
E…
as
a 34.3 32… 34.0 30…
p… % % % %
of
n…
s…
(1) Merger and acquisition-related costs represent certain costs associated with
acquisitions. These costs, presented on a before-tax effect basis, are included
in Non-GAAP Merger and Acquisition-related Costs Table.
Non-GAAP Merger and Acquisition-related Costs Table:
Three Nine
Months Months
Ended Ended
(In September Septemb…
thousa… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Amorti…
of
invent… $ — $ 6,957 $ — $ 12,973
fair
value
step up
Change
in fair
value
of 172 -2,721 16,231 2,681
busine…
acquis…
liabil…
Employ… 548 — 1,946 27,418
costs(…
Other
acquis… -88 442 186 3,105
costs(…
Merger
and $ 632 $ 4,678 $ 18,363 $ 46,177
acquis…
costs
(a) Primarily comprised of legal fees, advisory and consulting fees.
(b) Primarily comprised of severance, share-based compensation and termination
fees.
Non-GAAP Net Income Reconciliation Table:
Three Nine
Months Months
Ended Ended
(In Septem… Septemb…
thousa… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 141,171 $ 118,966 $ 417,042 $ 397,274
income…
Provis…
for 3,665 28,261 3,861 24,353
litiga…
net
Amorti…
of 29,574 29,843 88,660 88,834
intang…
Merger
and 632 4,678 18,363 46,177
acquis…
costs(…
Net
gain/(…
on 911 -946 -278 -2,255
strate…
invest…
Non-ca…
acquis…
foreign -60 -3,045 -277 -15,382
curren…
impacts
Restru… -473 2,260 8,674 22,909
costs
Bargain
purcha… — -3,800 -1,118 -114,3…
gain
Provis…
for
income
tax
benefit — -1,740 — -36,555
from
non-re…
tax
adjust…
Tax
effect
of -8,378 -15,127 -28,695 -40,034
adjust…
items
Non-GA…
net $ 167,042 $ 159,350 $ 506,232 $ 370,960
income…
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table for the
detail of these costs.
Non-GAAP Gross Profit Reconciliation Table:
Thr… Nine
Mon… Mon…
(In End… End…
th… Sep… Sep…
ex… 30, 30,
pe… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 763… $ 769… $ 2,3… $ 2,11…
sa…
Co…
of
sa…
(e… 232… 252… 708… 696,…
of
am…
of
in…
Am…
of 21,… 22,… 63,… 69,5…
in…
Gr… $ 509… $ 493… $ 1,5… $ 1,34…
Pr…
Am…
of
in…
fa… — 6,9… — 12,9…
va…
st…
up
Am…
of 21,… 22,… 63,… 69,5…
in…
Ad…
Gr… $ 530… $ 523… $ 1,6… $ 1,42…
Pr…
Gr…
Pr…
% 66.7 64.2 66.6 63.7
of % % % %
Net
Sa…
Ad…
Gr…
Pr… 69.5 68.1 69.4 67.6
% % % % %
of
Net
Sa…
Non-GAAP Diluted Earnings Per Share Reconciliation Table:
Three Nine
Months Months
(Per Ended Ended
share September September
amounts) 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Diluted
earnings
per $ 1.04 $ 0.88 $ 3.04 $ 2.90
share,
as
reported
Provisi…
for 0.03 0.21 0.03 0.18
litigat…
net
Amortiz…
of 0.22 0.22 0.65 0.65
intangi…
Merger
and — 0.03 0.13 0.34
acquisi…
costs(1)
Net
(gain)
loss 0.01 -0.01 — -0.02
from
strateg…
investm…
Non-cash
acquisi…
foreign — -0.02 — -0.11
currency
impacts
Restruc… — 0.02 0.06 0.17
costs
Bargain
purchase — -0.03 -0.01 -0.83
gain
Provisi…
for
income
tax
benefit — -0.01 — -0.27
from
non-rec…
tax
adjustm…
Tax
effect
of -0.06 -0.11 -0.21 -0.29
adjusti…
items
Non-GAAP
diluted
earnings $ 1.23 $ 1.18 $ 3.69 $ 2.70
per
share
(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above
for the detail of these costs.
*Amounts may not add due to rounding.
Non-GAAP Free Cash Flow Reconciliation Table:
Three Nine
Months Months
Ended Ended
(In Septem… Septemb…
thousa… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provid… $ 265,227 $ 249,696 $ 677,332 $ 504,860
by
operat…
activi…
Purcha…
of
proper… -40,389 -35,817 -113,172 -118,4…
and
equipm…
Free
cash $ 224,838 $ 213,879 $ 564,160 $ 386,378
flow
Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:
Curr…
Impa…
Three on Cons…
(In Mont… Repor… Curr… Curr…
thous… Ended Net Peri… Net
except Sept… Sales Net Sales
perce… 30, 2026 2025 Growth Sales Grow…
──────────────────────────────────────────────────────────────────────────────
Unit… $ 620,9… $ 617,… 0.5% $ — 0.5%
Stat…
Inte… 142,7… 151,… -5.7% -1,124 -5.0%
Total
net $ 763,7… $ 769,… -0.7% $ -1,124 -0.5%
sales
Curr…
Impa…
Nine on Cons…
(In Mont… Repor… Curr… Curr…
thous… Ended Net Peri… Net
except Sept… Sales Net Sales
perce… 30, 2026 2025 Growth Sales Grow…
──────────────────────────────────────────────────────────────────────────────
Unit… $ 1,844… $ 1,70… 8.4% $ — 8.4%
Stat…
Inte… 468,2… 410,… 14.1% 10,430 11.6%
Total
net $ 2,313… $ 2,11… 9.5% $ 10,430 9.0%
sales
Base Business and Nevro Corp. Net Sales Reconciliation Table:
Three Nine
Months Months
Ended Ended
(In Septemb… Septem…
thous… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
Sales
of $ 73,701 $ 99,254 $ 237,392 $ 193,839
Nevro
produ…
Net
Sales
of 690,018 669,794 2,075,… 1,918,6…
base
busin…
Total
net $ 763,719 $ 769,048 $ 2,313,… $ 2,112,5…
sales
Investor Contact:
Shagun Singh
Senior Vice President, Strategy and Investor Relations
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com